Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

60.16

-0.58 (0.95%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

160 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) has garnered mixed reviews from experts, highlighting both its potential and setbacks. While some analysts praise its solid dividend yield, promising drug pipeline, and recent earnings performance that exceeded expectations, others express concerns regarding the disappointing sales of its Cobenfy drug. Recent financial results indicate a modest sales growth of 3% and a significant 18% increase in its growth portfolio, albeit with a downturn in legacy drugs. Additionally, the company's management has raised its revenue guidance for 2025, which provides a glimmer of optimism for future performance. Overall, there is cautious optimism about a possible rebound if the growth portfolio continues to outperform older products.

Consensus

Mixed

Valuation

Undervalued

Similar

EliLilly, LLY

WAIT

Down 23% in the past 6 months. Pays a 5% dividend. Be patient and give the current CEO a chance to turn things around.

Wealthica Track your Stocks in your Watch List

TOP PICK

Big on immune oncology and cardio. Technically doesn't look great, but eventually "the train will come along and collect the mail bag". Makes a ton of $$ in NA. Wide moat. Concerns about pipeline, but he thinks it's pretty good. Limited downside. Yield is 4.9%.

Good pricing power. Because products are so specialized, FDA puts them on sort of a fast track.

(Analysts’ price target is $59.92)

COMMENT

In the past quarter, They recently bought 3 companies, including Mirati, a small oncology company, and Karuna who may develop a wonder drug to treat schizophrenia. BMY needs to buy companies, because their top 3 drugs face steep patent cliffs, like a blood-clot drug, accounting for over 61% of 2023 (Jan-Sept)'s sales.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly

The company has partnered with a Chinese pharma company for a new drug to lung and breast cancer patients. They will have exclusive rights outside of China. It trades at 13x earnings and supports a ROE of 26%. It has a good dividend, backed by a payout ratio under 60% of cash flow. The company has been prudentially using some cash reserves to aggressively buy back shares and retire debt. We recommend placing a stop at $44, looking to achieve $63 -- upside potential of 23%. Yield 4.4%

(Analysts’ price target is $62.82)

BUY

Disagrees with today's downgrade. BMY will produce $75 billion free cash flow over the next 5 years, which will transform them.

DON'T BUY

They don't have the drug pipeline that they used to have. Also, don't buy a stock only for the dividend.

BUY

Investors have given up on drug stocks, including BMY, but he won't. You must own a drug stock in your portfolio.

COMMENT

It has some real challenges from 2026 to 2030 when some of their drugs will come off patents. They will need to fill their pipeline. This is reflected in the 8X earnings multiple. As for Amgen, it has defensive characteristics but we need to make sure they execute their plans.

BUY

Trades under 9x earnings, has a ton of free cash flow and are buying back stock.

BUY

They have zero economic sensitivity (good) and has enough drugs in the pipeline to beat future estimates. Always pays an above-average dividend.

HOLD

In fine shape, can own it for the next 6-9 months of volatility. The way the market is, owning healthcare is safer than owning other things. Very defensive. He owns JNJ and NVO, but any of these companies will be fine.

DON'T BUY

A leaking boat that you need to bail out of. Their flagship drug, an oncology one, goes off patent in 2028. Their other drugs go off-patent in 2025-6. 80% of their 2021 revenues will be off-patent by 2028. Trades at 23x PE. All drug companies have these issues, but would rather buy a drug company that's less reliant on a key drug and trades cheaper.

BUY

BMY and AbbVie The line is blurred between biotech and pharma. He likes both spaces and both stocks. Aging demographics means more and more drugs. Both are have solid valuations. They pay income but also offer capital appreciation.

BUY

Trades at 9x earnings. Has a great pipeline of drugs. Pays a great dividend.

Showing 31 to 45 of 221 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Bristol Myers Squibb (BMY)